In general, variants are annotated in the databases in two different ways: 1) as hotspot mutations/CNVs/fusions with very well-known therapeutic implications (e.g., T790 M or exon 19 mutations in EGFR, HER2 amplification in breast cancer); or 2) as “any missense mutation” or just “any loss/gain of function” variant in those cases where there is no hotspot mutation known or all variants within a gene are studied (very common in clinical trials and preclinical studies). The gene discussed is EGFR; the disease is breast carcinoma.